구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS) |
Overview Company | Henry Ford Health System |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Malignant Glioma of Brain; Astrocytoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | - binding to DNA in mitochondria with pH values above 8 |
MoA Biomarker | biomarkers in fibrotic kidneys: lysyl oxidase-derived allysine (Lys Ald ) and transglutaminase 2 (TG2) |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PK |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Tumor control probability modeling of stereotactic radiosurgery and fractionated stereotactic radiosurgery for patients with brainstem metastases.. Evidence supports stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS) for brainstem metastases (BSMs). The optimal dose-fractionation schedule remains undefined. We evaluated tumor control probability (TCP), overall surviva… |
Clinical Safety signal | Tumor control probability modeling of stereotactic radiosurgery and fractionated stereotactic radiosurgery for patients with brainstem metastases.. Evidence supports stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS) for brainstem metastases (BSMs). The optimal dose-fractionation schedule remains undefined. We evaluated tumor control probability (TCP), overall surviva… |
Clinical Reported PFS | 5 |
Clinical Reported OS | 5 |
Clinical Result source | ClinicalTrials.gov NCT04588246 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT04588246 |
Preclinical Animal (cat.) | Rat |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS) |
Overview Company | Henry Ford Health System |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Malignant Glioma of Brain; Astrocytoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | - binding to DNA in mitochondria with pH values above 8 |
MoA Biomarker | biomarkers in fibrotic kidneys: lysyl oxidase-derived allysine (Lys Ald ) and transglutaminase 2 (TG2) |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PK |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Tumor control probability modeling of stereotactic radiosurgery and fractionated stereotactic radiosurgery for patients with brainstem metastases.. Evidence supports stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS) for brainstem metastases (BSMs). The optimal dose-fractionation schedule remains undefined. We evaluated tumor control probability (TCP), overall surviva… |
Clinical Safety signal | Tumor control probability modeling of stereotactic radiosurgery and fractionated stereotactic radiosurgery for patients with brainstem metastases.. Evidence supports stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS) for brainstem metastases (BSMs). The optimal dose-fractionation schedule remains undefined. We evaluated tumor control probability (TCP), overall surviva… |
Clinical Reported PFS | 5 |
Clinical Reported OS | 5 |
Clinical Result source | ClinicalTrials.gov NCT04588246 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT04588246 |
Preclinical Animal (cat.) | Rat |
추천 비교
추천 비교